Drug Profile
Research programme: antiviral therapeutics - Cocrystal Pharma
Alternative Names: CC 2850; CC-1845; CC-2068; CC-2069; CC-31326; CDI-244Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Cocrystal Discovery
- Developer Cocrystal Pharma Inc
- Class Antivirals; Small molecules
- Mechanism of Action Enzyme modulators; Hepatitis C virus NS 5 protein inhibitors; Polymerase inhibitors; RNA replicase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Norovirus infections
- Discontinued Dengue; Ebola virus infections; Hepatitis B; Hepatitis C; Human papillomavirus infections; Influenza virus infections; Rhinovirus infections
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Norovirus-infections in USA (PO)
- 06 Jan 2022 Preclinical development is ongoing for Norovirus infections in USA (PO) (Cocrystal Pharma pipeline, January 2022)
- 06 Jan 2022 Discontinued - Preclinical for Influenza virus infections in USA (Inhalation) before January 2022 (Cocrystal Pharma pipeline, January 2022)